B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

0.00

B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Neutral and lowers the price target from $550 to $542.